Bruker (NASDAQ:BRKR) Upgraded at TD Cowen

TD Cowen upgraded shares of Bruker (NASDAQ:BRKR) to a hold rating in a research note released on Monday morning,Zacks.com reports.

A number of other brokerages have also commented on BRKR. Jefferies Financial Group set a $50.00 price objective on Bruker in a report on Thursday, February 12th. Barclays lowered their price objective on Bruker from $50.00 to $45.00 and set an “overweight” rating on the stock in a report on Tuesday. Wells Fargo & Company increased their price objective on Bruker from $48.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Guggenheim lowered their price objective on Bruker from $58.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, March 30th. Finally, Bank of America increased their price objective on Bruker from $43.00 to $60.00 and gave the company a “buy” rating in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $49.38.

Bruker Stock Performance

Shares of NASDAQ BRKR opened at $39.48 on Monday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73. The firm has a market cap of $6.01 billion, a price-to-earnings ratio of -263.20, a P/E/G ratio of 2.39 and a beta of 1.20. The business’s 50-day simple moving average is $37.51 and its 200-day simple moving average is $41.70. Bruker has a 52 week low of $28.53 and a 52 week high of $56.22.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). The company had revenue of $977.20 million for the quarter, compared to analyst estimates of $964.61 million. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The business’s revenue was down .2% on a year-over-year basis. During the same period in the prior year, the company posted $0.76 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities research analysts expect that Bruker will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd were issued a $0.05 dividend. The ex-dividend date of this dividend was Monday, March 23rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Bruker’s dividend payout ratio (DPR) is -133.33%.

Insider Transactions at Bruker

In other Bruker news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $35.44, for a total value of $70,880.00. Following the completion of the sale, the vice president owned 128,443 shares in the company, valued at approximately $4,552,019.92. This trade represents a 1.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 27.30% of the stock is owned by company insiders.

Institutional Trading of Bruker

Hedge funds have recently modified their holdings of the company. Los Angeles Capital Management LLC bought a new stake in shares of Bruker in the 4th quarter worth approximately $26,000. Allworth Financial LP lifted its position in shares of Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after acquiring an additional 257 shares during the period. Parallel Advisors LLC lifted its position in shares of Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after acquiring an additional 479 shares during the period. Spire Wealth Management lifted its position in shares of Bruker by 85.3% in the 3rd quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock worth $47,000 after acquiring an additional 665 shares during the period. Finally, Summit Securities Group LLC bought a new stake in shares of Bruker in the 4th quarter worth approximately $50,000. Institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.